Idecabtagen vicleucel (Abecma®) – Multiple myeloma (MM), at least 3 previous therapies
Characteristics
| Start date | 01.01.2022 |
|---|---|
| Resolution | 16.06.2022 |
| INN | Idecabtagen vicleucel |
| Brand name | Abecma® |
| Pharm. company | Bristol-Myers Squibb GmbH & Co KGaA |
| G-BA procedure ID | 2022-01-01-D-779 |
| Therapeutic area | Oncological diseases ORPHAN |
| Reason for procedure | Initial assessment |
| Regulatory status | ATMP (CAR-T) |
| Indication (German) |
|---|
|
Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Adults with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies, including an immunomodulator, a proteasome inhibitor and an anti-CD38 antibody, and have shown disease progression on the last therapy. | Not applicable |
9. Associated procedures
| Resolution | INN | Brand name | Indication | Patients | Additional benefit |
|---|---|---|---|---|---|
| 01.01.2022 – 16.06.2022 | Idecabtagen vicleucel | Abecma® | Multiple myeloma (MM), at least 3 previous therapies | 1,200 – 1,300 |
<< List of all resolutions